Breast cancer drug shows promise for treating, preventing progestin-dependent tumors

(University of Missouri-Columbia) Recent studies suggest that human breast risk is increased by outside exposure to the hormone progestin, such as during hormone replacement therapy. Now, a University of Missouri study suggests that PRIMA-1, a small molecule that targets the most common mutated , p53, in human cells, has potential as a novel chemotherapeutic treatment for progestin-accelerated human breast .


Read more

Related posts

Leave a Reply